30 DAY MORTALITY FOLLOWING ANDEXANET ALFA IN ANNEXA-4 COMPARED WITH PROTHROMBIN COMPLEX CONCENTRATE (PCC) THERAPY IN THE ORANGE STUDY FOR LIFE THREATENING NON-VITAMIN K ORAL ANTICOAGULANT (NOAC) RELATED BLEEDING | AMiner
30 DAY MORTALITY FOLLOWING ANDEXANET ALFA IN ANNEXA-4 COMPARED WITH PROTHROMBIN COMPLEX CONCENTRATE (PCC) THERAPY IN THE ORANGE STUDY FOR LIFE THREATENING NON-VITAMIN K ORAL ANTICOAGULANT (NOAC) RELATED BLEEDING
Guy's and St Thomas’ Hospitals NHS Foundation Trust
被引用11|浏览41
摘要
Life-threatening NOAC related major bleeding is associated with high mortality. Off-label PCC is currently recommended in some guidelines as well as the approved specific antidote, andexanet alfa (andexanet). There are no randomised controlled trials comparing these therapies and hence we undertook
原文链接
分享
引用
